Traders should monitor for the upcoming definitive proxy statement, regulatory filings, and potential competing bids. The acquisition could lead to operational synergies and revenue expansion through Danaher's global commercial infrastructure. Consider positioning for deal closure in the coming months, barring regulatory or shareholder hurdles.
Price Chart
Executive Summary
Danaher Corporation has announced an agreement to acquire Masimo Corporation, a medical technology company specializing in patient monitoring solutions. The DFAN14A filing consists of communications from Danaher leadership to Masimo employees, confirming the proposed transaction and expressing enthusiasm about combining the two organizations to expand global impact in diagnostics and patient care.
Key Facts
- Danaher Corporation is acquiring Masimo Corporation.
- The deal is intended to combine Danaher's diagnostics platform with Masimo's patient monitoring and acute care innovations.
- Julie Sawyer Montgomery, Executive Vice President of Danaher's Diagnostics segment, communicated directly with Masimo employees to affirm commitment and vision.
- The transaction is subject to regulatory approvals, stockholder approval, and other customary closing conditions.
- Until closing, Masimo will continue operating independently under current leadership.
Financial Impact
Deal value not disclosed in this filing, but Masimo's market cap is $9.4B as of filing date.
Risk Factors
- Failure to obtain regulatory approvals or Masimo stockholder approval.
- Potential for competing acquisition offers.
- Integration risks post-closing.
- Litigation related to the transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0001193125-26-082686 |
| Document: 0001193125-26-082686-index-headers.html | 0001193125-26-082686 |
| Document: 0001193125-26-082686-index.html | 0001193125-26-082686 |
| Document: 0001193125-26-082686.txt | 0001193125-26-082686 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 15-12G | — | awaiting T+5 | — | — |
Jun 10, 2026 16w ago | 8-K | $179.95 $179.95 | · 0.00% | ▼ −2.14% | — |
May 4, 2026 21w ago | 8-K | $177.90 $178.08 | ▲ +0.10% | ▼ −2.83% | — |
Apr 21, 2026 23w ago | Court Ruling | $178.21 $178.10 | ▲ +0.06% | ▲ +1.15% | — |
Apr 1, 2026 26w ago | DEFM14A | $177.95 $177.88 | ▼ −0.04% | ▼ −3.80% | — |
Mar 18, 2026 28w ago | PREM14A | $178.51 $176.87 | ▼ −0.92% | ▲ +1.29% | — |
Feb 27, 2026 30w ago | DFAN14A | $175.27 $175.42 | ▲ +0.09% | ▲ +1.29% | — |
Jan 23, 2026 36w ago | Court Ruling | $140.64 $137.02 | ▼ −2.57% | ▼ −2.96% | — |
Jan 23, 2026 36w ago | Court Ruling | $140.64 $137.02 | ▼ −2.57% | ▼ −2.96% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access